Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 783 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bioequivalence Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ropinirole 0.25 mg Tablets Under Fasting Conditions

NCT00829504
View directory record Official record
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.

NCT04390776
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-06651600
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Hollywood, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg)

NCT00978055
View directory record Official record
Conditions
Healthy
Interventions
1: Liothyronine Sodium Tablets, 2: Cytomel® Tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2009 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851095
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects

NCT07015671
View directory record Official record
Conditions
Bioequivalence Study in Healthy Subjects, PK/PD
Interventions
10 mg Torsemide tablet, 25 mg Aldactone (Spironolactone) tablet, FDC (12 mg ER Torsemide + 15mg Spironolactone) tablet
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

NCT00552708
View directory record Official record
Conditions
Hypertension
Interventions
COREG CR, Lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2010 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Determine the Fed Bioequivalence of Reformulated OXY Tablets and Original OxyContin® (OXY) Tablets

NCT01101178
View directory record Official record
Conditions
Healthy
Interventions
Reformulated OXY (oxycodone HCl), Original OxyContin® (OXY) (oxycodone HCl)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 10, 2011 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

NCT03097861
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
67
States / cities
Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg

NCT00649480
View directory record Official record
Conditions
Healthy
Interventions
BALSALAZIDE DISODIUM CAPSULES, 750 MG, COLAZAL® Capsules 750 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects

NCT03796013
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Entrectinib Form A, Entrectinib Form C
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 4 Interventional

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

NCT01889758
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)

NCT01844804
View directory record Official record
Conditions
Healthy
Interventions
PF-06438179, Remicade
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Pantoprazole 40 mg DR Tablets and Protonix 40 mg Tablets

NCT01179646
View directory record Official record
Conditions
Healthy
Interventions
Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet
Drug
Lead sponsor
Kremers Urban Development Company
Industry
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ABX-002 Bioequivalence and Effect of Food Study in Healthy Adult Participants

NCT07652697
View directory record Official record
Conditions
Healthy
Interventions
ABX-002
Drug
Lead sponsor
Autobahn Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets

NCT06801418
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Adagrasib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

NCT00835497
View directory record Official record
Conditions
Healthy
Interventions
5 mg/500 mg Glipizide Metformin Hydrochloride Tablets, 5 mg/500 mg METAGLIP™ Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2009 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions

NCT00865215
View directory record Official record
Conditions
Healthy
Interventions
Propranolol Hydrochloride Extended Release Capsules 160 mg, INDERAL® LA 160 mg Capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

NCT04561115
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Gamunex-C, IVIG-PEG
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Formulations of Ixekizumab in Healthy Participants

NCT04259346
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Daytona Beach, Florida • Miami, Florida • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets

NCT03056703
View directory record Official record
Conditions
Pain
Interventions
Acetylsalicylic acid (Aspirin, BAY1019036)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

NCT00829764
View directory record Official record
Conditions
Healthy
Interventions
Doxycycline Monohydrate
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

NCT01903109
View directory record Official record
Conditions
Dry Mouth
Interventions
Cevimeline
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 22, 2026, 9:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drospirenone/Ethinyl Estradiol (3 mg/0.02 mg) Tablets Under Non-Fasting Conditions

NCT01182207
View directory record Official record
Conditions
Healthy
Interventions
Drospirenone/Ethinyl Estradiol (Gianvi®), YAZ®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 22, 2026, 9:59 AM EDT